A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma

BACKGROUND: Cytokine-based drugs are currently being explored as alternative cancer immunotherapies. While the cytokine interleukin-18 (IL-18) has immunostimulatory effects, it is negatively regulated by a secreted high-affinity binding protein, IL-18BP, that functions as an immune checkpoint that l...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenfeld, David, Djureinovic, Dijana, Zhang, Lin, Mann, Jacqueline, Huck, John, Jilaveanu, Lucia, Ring, Aaron, Kluger, Harriet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Rapid Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445567/
http://dx.doi.org/10.1093/oncolo/oyad216.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445567/
http://dx.doi.org/10.1093/oncolo/oyad216.010

Ejemplares similares